A Phase IV, Open-label, Single Arm, Multicentre Trial of Grazoprevir/Elbasvir for Genotype 1 or 4 in People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use
Phase of Trial: Phase IV
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms DARLO-C
- 14 Jun 2017 Planned End Date changed from 1 Dec 2020 to 1 Oct 2021.
- 14 Jun 2017 Planned primary completion date changed from 1 Dec 2020 to 1 Apr 2021.
- 14 Jun 2017 Status changed from not yet recruiting to recruiting.